- Home
- NPCT vs CERS Comparison
NPCT vs CERS Comparison
Compare NPCT & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPCT | CERS |
|---|---|---|
| Founded | 2020 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.2M | 276.0M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | NPCT | CERS |
|---|---|---|
| Price | $10.12 | $1.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 118.7K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.82% | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $20.00 |
| Revenue Next Year | N/A | $9.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $9.77 | $1.12 |
| 52 Week High | $11.31 | $2.96 |
Technical Indicators
Market Signals| Indicator | NPCT | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 22.16 | 32.71 |
| Support Level | N/A | $1.27 |
| Resistance Level | $10.32 | $2.26 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 1.80 | 5.24 |
Price Performance
Historical ComparisonAbout NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.